Symbols / CGON Stock $56.67 +4.17% CG Oncology, Inc.

Healthcare • Biotechnology • United States • NMS
CGON (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Arthur Kuan
Exch · Country NMS · United States
Market Cap 5.00B
Enterprise Value 3.93B
Income -186.74M
Sales 5.07M
FCF (ttm) -105.89M
Book/sh 12.40
Cash/sh 12.20
Employees 142
Insider 10d —
IPO Jan 25, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -20.39
PEG —
P/S 985.69
P/B 4.57
P/C —
EV/EBITDA -18.48
EV/Sales 774.95
Quick Ratio 30.60
Current Ratio 31.30
Debt/Eq 0.69
LT Debt/Eq —
EPS (ttm) -2.34
EPS next Y -2.78
EPS Growth —
Revenue Growth 19.83%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-07
Earnings (prior) 2026-05-08
ROA -14.42%
ROE -20.79%
ROIC —
Gross Margin 0.00%
Oper. Margin -61.30%
Profit Margin 0.00%
Shs Outstand 88.20M
Shs Float 65.82M
Insider Own 0.23%
Instit Own 110.08%
Short Float 11.32%
Short Ratio 10.60
Short Interest 9.81M
52W High 75.50
vs 52W High -24.94%
52W Low 23.65
vs 52W Low 139.62%
Beta 0.31
Impl. Vol. 3.13%
Rel Volume 1.02
Avg Volume 1.20M
Volume 1.22M
Target (mean) $90.29
Tgt Median $88.50
Tgt Low $80.00
Tgt High $108.00
# Analysts 14
Recom None
Prev Close $54.40
Price $56.67
Change 4.17%
About

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$90.29
Mean price target
2. Current target
$56.67
Latest analyst target
3. DCF / Fair value
$-21.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$56.67
Low
$80.00
High
$108.00
Mean
$90.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-19 init Wolfe Research — → Peer Perform —
2026-05-18 reit HC Wainwright & Co. Buy → Buy $100
2026-05-14 reit Truist Securities Buy → Buy $82
2026-05-11 main JP Morgan Overweight → Overweight $96
2026-05-11 main RBC Capital Outperform → Outperform $81
2026-05-11 reit Truist Securities Buy → Buy $77
2026-05-11 main Wedbush Outperform → Outperform $80
2026-04-27 main RBC Capital Outperform → Outperform $79
2026-04-17 main JP Morgan Overweight → Overweight $91
2026-04-07 main HC Wainwright & Co. Buy → Buy $100
2026-02-27 main HC Wainwright & Co. Buy → Buy $80
2026-02-10 main Truist Securities Buy → Buy $75
2026-01-21 main RBC Capital Outperform → Outperform $73
2026-01-16 main Piper Sandler Overweight → Overweight $70
2026-01-12 main Truist Securities Buy → Buy $66
2025-12-11 init Wedbush — → Outperform $70
2025-11-24 init Truist Securities — → Buy $62
2025-11-17 main RBC Capital Outperform → Outperform $61
2025-10-08 init Guggenheim — → Buy $90
2025-09-26 main JP Morgan Overweight → Overweight $47
News
RSS: Latest CGON news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-04 POST LEONARD E Director — 1,000 $54.50 $54,500
2026-06-04 POST LEONARD E Director — 1,000 $0.60 $600
2026-04-17 MULAY JAMES J. PH.D. Director — 15,600 $73.01 $1,138,956
2026-04-17 MULAY JAMES J. PH.D. Director — 15,600 $36.63 $571,428
2026-03-16 MULAY JAMES J. PH.D. Director — 1,964 $63.50 $124,714
2026-03-16 MULAY JAMES J. PH.D. Director — 1,964 $3.72 $18,926
2026-03-12 KUAN ARTHUR Chief Executive Officer — 64,612 $1.72 $111,133
2026-03-04 KUAN ARTHUR Chief Executive Officer — 102,871 $1.72 $176,938
2026-01-09 MULAY JAMES J. PH.D. Director — 11,145 $44.16 $584,799
2026-01-09 MULAY JAMES J. PH.D. Director — 11,145 $3.72 $134,515
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.04
+254.70%
1.14
+458.33%
0.20
+6.81%
0.19
Operating Revenue
4.04
+254.70%
1.14
+458.33%
0.20
+6.81%
0.19
Cost Of Revenue
4.65
0.00
0.00
—
Reconciled Cost Of Revenue
4.65
0.00
0.00
—
Gross Profit
-0.61
-153.29%
1.14
+458.33%
0.20
—
Operating Expense
190.17
+64.21%
115.81
+108.08%
55.65
+57.05%
35.44
Research And Development
116.64
+42.07%
82.10
+79.45%
45.75
+57.61%
29.03
Selling General And Administration
73.53
+118.16%
33.70
+240.40%
9.90
+54.51%
6.41
General And Administrative Expense
73.53
+118.16%
33.70
+240.40%
9.90
+54.51%
6.41
Salaries And Wages
39.25
+83.46%
21.39
+286.00%
5.54
+67.43%
3.31
Other Gand A
34.28
+178.45%
12.31
+24.34%
9.90
+219.59%
3.10
Total Expenses
194.81
+68.23%
115.81
+108.08%
55.65
+57.05%
35.44
Operating Income
-190.77
-66.37%
-114.67
-106.80%
-55.45
-57.32%
-35.25
Total Operating Income As Reported
-190.77
-66.37%
-114.67
-106.80%
-55.45
-57.32%
-35.25
EBITDA
-189.33
-65.16%
-114.63
-106.80%
-55.43
-57.34%
-35.23
Normalized EBITDA
-189.33
-65.16%
-114.63
-106.80%
-55.43
-57.34%
-35.23
Reconciled Depreciation
1.45
+4415.63%
0.03
+88.24%
0.02
+13.33%
0.01
EBIT
-190.77
-66.37%
-114.67
-106.80%
-55.45
-57.32%
-35.25
Net Income
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Pretax Income
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Net Non Operating Interest Income Expense
29.93
+12.42%
26.62
+285.63%
6.90
+690500.00%
-0.00
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
29.93
+12.42%
26.62
+285.63%
6.90
+690500.00%
-0.00
Interest Expense
—
—
—
0.00
Interest Income Non Operating
29.93
+12.42%
26.62
+285.63%
6.90
—
Interest Income
29.93
+12.42%
26.62
+285.63%
6.90
—
Other Income Expense
-0.15
-5166.67%
0.00
+104.84%
-0.06
+68.37%
-0.20
Other Non Operating Income Expenses
-0.15
-5166.67%
0.00
+104.84%
-0.06
+68.37%
-0.20
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Net Income From Continuing Operation Net Minority Interest
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Net Income From Continuing And Discontinued Operation
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Net Income Continuous Operations
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Normalized Income
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Net Income Common Stockholders
-161.00
-82.87%
-88.04
-29.85%
-67.80
-54.83%
-43.79
Diluted EPS
-2.08
-47.52%
-1.41
+90.99%
-15.65
-33.65%
-11.71
Basic EPS
-2.08
-47.52%
-1.41
+90.99%
-15.65
-33.65%
-11.71
Basic Average Shares
77.30
+23.69%
62.50
+1343.03%
4.33
+15.77%
3.74
Diluted Average Shares
77.30
+23.69%
62.50
+1343.03%
4.33
+15.77%
3.74
Diluted NI Availto Com Stockholders
-161.00
-82.87%
-88.04
-29.85%
-67.80
-54.83%
-43.79
Preferred Stock Dividends
—
—
19.19
+129.97%
8.35
Total Other Finance Cost
—
—
-6.90
-690500.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
791.59
+4.87%
754.80
+278.72%
199.30
+34.89%
147.75
Current Assets
759.48
+0.70%
754.21
+288.52%
194.12
+31.87%
147.21
Cash Cash Equivalents And Short Term Investments
742.15
+0.02%
742.00
+295.37%
187.67
+30.80%
143.48
Cash And Cash Equivalents
32.49
-87.36%
257.07
+3009.94%
8.27
-90.62%
88.14
Other Short Term Investments
709.66
+46.34%
484.93
+170.29%
179.41
+224.20%
55.34
Receivables
0.69
0.00
-100.00%
0.09
-69.64%
0.30
Accounts Receivable
0.69
0.00
—
—
Other Receivables
—
0.78
+748.91%
0.09
-69.64%
0.30
Inventory
1.56
0.00
—
—
Other Current Assets
15.07
+23.38%
12.21
+92.07%
6.36
+85.69%
3.42
Total Non Current Assets
32.12
+5371.38%
0.59
-88.66%
5.18
+860.48%
0.54
Net PPE
19.57
+3868.97%
0.49
+0.41%
0.49
-2.96%
0.51
Gross PPE
21.04
+3527.76%
0.58
+18.13%
0.49
-2.96%
0.51
Accumulated Depreciation
-1.47
-1594.25%
-0.09
—
—
Properties
0.00
0.00
—
—
Machinery Furniture Equipment
0.59
+64.07%
0.36
—
—
Other Properties
9.95
+4403.62%
0.22
-54.99%
0.49
-2.96%
0.51
Leases
10.50
0.00
—
—
Goodwill And Other Intangible Assets
10.87
0.00
—
—
Goodwill
10.30
0.00
—
—
Other Intangible Assets
0.57
—
—
—
Non Current Deferred Assets
—
0.00
-100.00%
4.67
0.00
Other Non Current Assets
1.68
+1685.11%
0.09
+394.74%
0.02
-42.42%
0.03
Total Liabilities Net Minority Interest
38.99
+82.03%
21.42
+47.61%
14.51
-35.71%
22.57
Current Liabilities
30.84
+44.31%
21.37
+49.91%
14.25
-7.62%
15.43
Payables And Accrued Expenses
20.62
+37.88%
14.95
+53.41%
9.75
+128.37%
4.27
Payables
5.71
-12.32%
6.52
+101.02%
3.24
+229.14%
0.98
Accounts Payable
5.71
-12.32%
6.52
+101.02%
3.24
+229.14%
0.98
Current Accrued Expenses
14.90
+76.66%
8.44
+29.68%
6.50
+98.14%
3.28
Pensionand Other Post Retirement Benefit Plans Current
8.22
+41.83%
5.79
+105.28%
2.82
+53.96%
1.83
Current Debt And Capital Lease Obligation
0.92
+391.94%
0.19
-14.29%
0.22
-97.63%
9.15
Current Debt
—
—
—
8.97
Other Current Borrowings
—
—
—
8.97
Current Capital Lease Obligation
0.92
+391.94%
0.19
-14.29%
0.22
+14.81%
0.19
Current Deferred Liabilities
0.29
0.00
-100.00%
1.02
0.00
Current Deferred Revenue
0.29
0.00
—
—
Other Current Liabilities
0.80
+83.94%
0.44
-3.33%
0.45
+160.69%
0.17
Total Non Current Liabilities Net Minority Interest
8.15
+15580.77%
0.05
-79.77%
0.26
-96.40%
7.14
Long Term Debt And Capital Lease Obligation
6.11
+11642.31%
0.05
-78.69%
0.24
-96.41%
6.79
Long Term Debt
3.00
—
—
6.53
Long Term Capital Lease Obligation
3.11
+5873.08%
0.05
-78.69%
0.24
-5.06%
0.26
Non Current Deferred Liabilities
0.31
0.00
—
—
Non Current Deferred Taxes Liabilities
0.31
0.00
—
—
Other Non Current Liabilities
1.74
—
0.01
-96.31%
0.35
Preferred Securities Outside Stock Equity
—
—
—
202.87
Stockholders Equity
752.60
+2.62%
733.38
+296.87%
184.79
+47.62%
125.18
Common Stock Equity
752.60
+2.62%
733.38
+695.76%
-123.10
-58.44%
-77.69
Capital Stock
0.01
+0.00%
0.01
-100.00%
307.89
+51.77%
202.87
Common Stock
0.01
+0.00%
0.01
0.00
0.00
Preferred Stock
—
0.00
-100.00%
307.89
+51.77%
202.87
Share Issued
80.69
+5.95%
76.15
+19.96%
63.48
+0.00%
63.48
Ordinary Shares Number
80.69
+5.95%
76.15
+19.96%
63.48
+0.00%
63.48
Additional Paid In Capital
1,131.57
+18.94%
951.35
+13804.56%
6.84
+87.86%
3.64
Retained Earnings
-378.98
-73.86%
-217.98
-67.75%
-129.94
-59.76%
-81.33
Total Equity Gross Minority Interest
752.60
+2.62%
733.38
+296.87%
184.79
+47.62%
125.18
Total Capitalization
755.60
+3.03%
733.38
+296.87%
184.79
+40.30%
131.71
Working Capital
728.64
-0.57%
732.84
+307.43%
179.87
+36.49%
131.78
Invested Capital
755.60
+3.03%
733.38
+695.76%
-123.10
-97.93%
-62.20
Total Debt
7.02
+2850.00%
0.24
-48.37%
0.46
-97.11%
15.94
Capital Lease Obligations
4.02
+1589.50%
0.24
-48.37%
0.46
+3.36%
0.45
Net Tangible Assets
741.73
+1.14%
733.38
+296.87%
184.79
+47.62%
125.18
Tangible Book Value
741.73
+1.14%
733.38
+695.76%
-123.10
-58.44%
-77.69
Preferred Stock Equity
—
—
307.89
+51.77%
202.87
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-132.35
-68.14%
-78.71
-72.32%
-45.68
-53.26%
-29.80
Cash Flow From Continuing Operating Activities
-132.35
-68.14%
-78.71
-72.32%
-45.68
-53.26%
-29.80
Net Income From Continuing Operations
-161.00
-82.87%
-88.04
-81.12%
-48.61
-37.14%
-35.44
Depreciation Amortization Depletion
1.45
+4415.63%
0.03
+88.24%
0.02
+13.33%
0.01
Depreciation And Amortization
1.45
+4415.63%
0.03
+88.24%
0.02
+13.33%
0.01
Other Non Cash Items
-0.73
-3236.36%
-0.02
-102.69%
0.82
+60.90%
0.51
Stock Based Compensation
26.68
+133.96%
11.40
+646.20%
1.53
+126.04%
0.68
Operating Gains Losses
—
—
—
—
Unrealized Gain Loss On Investment Securities
-1.01
+79.69%
-4.99
-73.63%
-2.88
0.00
Change In Working Capital
2.28
-21.68%
2.91
-15.50%
3.44
-22.53%
4.44
Change In Receivables
-0.32
0.00
0.00
—
Changes In Account Receivables
-0.32
0.00
0.00
—
Change In Inventory
-0.44
0.00
0.00
—
Change In Prepaid Assets
-1.90
+67.03%
-5.76
-111.60%
-2.72
-353.77%
1.07
Change In Payables And Accrued Expense
7.01
-19.81%
8.74
+42.19%
6.15
+85.55%
3.31
Change In Accrued Expense
8.65
+58.28%
5.47
+32.17%
4.14
+24.16%
3.33
Change In Payable
-1.64
-150.20%
3.27
+62.77%
2.01
+11277.78%
-0.02
Change In Account Payable
-1.64
-150.20%
3.27
+62.77%
2.01
+11277.78%
-0.02
Change In Other Current Assets
-1.58
-2012.00%
-0.07
-676.92%
0.01
-75.00%
0.05
Change In Other Current Liabilities
-0.49
0.00
0.00
—
Investing Cash Flow
-245.82
+18.27%
-300.76
-148.17%
-121.19
-118.95%
-55.35
Cash Flow From Continuing Investing Activities
-245.82
+18.27%
-300.76
-148.17%
-121.19
-118.95%
-55.35
Net PPE Purchase And Sale
-0.13
+42.74%
-0.23
0.00
+100.00%
-0.01
Purchase Of PPE
-0.13
+42.74%
-0.23
0.00
+100.00%
-0.01
Capital Expenditure
-0.13
+42.74%
-0.23
—
-0.01
Net Investment Purchase And Sale
-223.72
+25.56%
-300.53
-147.97%
-121.19
-119.01%
-55.34
Purchase Of Investment
-1,067.86
-2.10%
-1,045.94
-102.07%
-517.61
-835.36%
-55.34
Sale Of Investment
844.14
+13.24%
745.41
+88.04%
396.42
0.00
Net Business Purchase And Sale
-21.97
0.00
0.00
—
Purchase Of Business
-21.97
0.00
0.00
—
Financing Cash Flow
153.59
-75.55%
628.28
+622.18%
87.00
-27.32%
119.69
Cash Flow From Continuing Financing Activities
153.59
-75.55%
628.28
+622.18%
87.00
-27.32%
119.69
Net Issuance Payments Of Debt
0.00
+100.00%
-0.36
+97.76%
-16.29
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-0.36
+97.76%
-16.29
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-0.36
+97.76%
-16.29
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-0.36
+97.76%
-16.29
0.00
Net Common Stock Issuance
147.45
-76.58%
629.47
0.00
-100.00%
0.17
Proceeds From Stock Option Exercised
6.46
+148.40%
2.60
+24.83%
2.08
+1154.22%
0.17
Net Other Financing Charges
-0.32
+90.77%
-3.42
-0.09%
-3.42
—
Changes In Cash
-224.58
-190.26%
248.80
+411.48%
-79.88
-331.29%
34.54
Beginning Cash Position
257.07
+3009.94%
8.27
-90.62%
88.14
+64.42%
53.61
End Cash Position
32.49
-87.36%
257.07
+3009.94%
8.27
-90.62%
88.14
Free Cash Flow
-132.48
-67.81%
-78.95
-72.83%
-45.68
-53.19%
-29.82
Interest Paid Supplemental Data
0.10
0.00
-100.00%
0.38
-65.54%
1.09
Income Tax Paid Supplemental Data
0.02
0.00
0.00
0.00
Amortization Of Securities
-1.01
+79.69%
-4.99
-73.63%
-2.88
0.00
Common Stock Issuance
147.45
-76.58%
629.47
0.00
-100.00%
0.17
Issuance Of Capital Stock
147.45
-76.58%
629.47
+501.63%
104.63
-12.47%
119.53
Net Preferred Stock Issuance
0.00
0.00
-100.00%
104.63
-12.47%
119.53
Preferred Stock Issuance
0.00
0.00
-100.00%
104.63
-12.47%
119.53
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category